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Nephrogenic Systemic Fibrosis is a rare condition appearing only in patients with severe renal impairment or failure
and presents with dermal lesions and involvement of internal organs. Although many cases are mild, an estimated
5 % have a progressive debilitating course. To date, there is no known effective treatment thus stressing the
necessity of ample prevention measures. An association with the use of Gadolinium based contrast agents (GBCA)
makes Nephrogenic Systemic Fibrosis a potential side effect of contrast enhanced magnetic resonance imaging and
offers the opportunity for prevention by limiting use of gadolinium based contrast agents in renal failure patients. In
itself toxic, Gadolinium is embedded into chelates that allow its safe use as a contrast agent. One NSF theory is that
Gadolinium chelates distribute into the extracellular fluid compartment and set Gadolinium ions free, depending on
multiple factors among which the duration of chelates exposure is directly related to the renal function. Major
medical societies both in Europe and in North America have developed guidelines for the usage of GBCA. Since the
establishment of these guidelines and the increased general awareness of this condition, the occurrence of NSF has
been nearly eliminated. Giving an overview over the current knowledge of NSF pathobiochemistry, pathogenesis
and treatment options this review focuses on the guidelines of the European Medicines Agency, the European
Society of Urogenital Radiology, the FDA and the American College of Radiology from 2008 up to 2011 and the
transfer of this knowledge into every day practice.Review
Cardiovascular Magnetic Resonance (CMR) has gained
an increasingly important role among the diagnostic
methods due to its superb soft tissue imaging qualities
without ionizing radiation and minimal risks. CMR is
one of the uprising areas of MRI offering deep insight in
both cardiac structure and function which minimizes the
risks of failing to make an accurate diagnosis or resorting
to more invasive tests [1]. Use of contrast enhanced
imaging techniques allows the assessment of perfusion,
tissue viability and detailed angiographic studies. The
overwhelming majority of these techniques use Gadolinium
based contrast agents (GBCAs). From the early days of
GBCA enhanced imaging, these contrast agents were
considered safe with only rare allergic reactions or local
irritation from extravasations. However, in 1997, a new
disease emerged, originally called Nephrogenic Fibrosing* Correspondence: Reiter_T@medizin.uni-wuerzburg.de
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medium, provided the original work is properDermopathy. It was first described by Cowper in 2001 [2]
and the relationship to GBCA exposure has been strongly
suspected since 2006 [3-7]. Later this entity was renamed
Nephrogenic Systemic Fibrosis (NSF) when involvement of
internal organs was discovered. An NSF Registry, www.
icnfdr.org documented over 355 cases that all occurred in
patients on dialysis or with severe renal dysfunction [8].
However since the connection between NSF and GBCAs
has become known changes in MRI protocols with the
focus on prevention has led to a decrease in NSF incidence.
Reports are showing virtually no new NSF cases since 2008
in both patients with normal renal function and patients
with renal impairment [9-11] in spite of continued use of
GBCA, albeit at lower doses.
Here we review the clinical features of NSF and show
how to use GBCA safely in patients at risk for NSF.
Pathobiochemistry of gadolinium
Gadolinium is one of the 14 elements of the lanthanide
group. Virtually all of its compounds contain it as the
paramagnetic Gd3+ ion which has seven unpairedtd. This is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
Reiter et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:31 Page 2 of 11
http://www.jcmr-online.com/content/14/1/31electrons in its half-filled 4 f outer shell. Gd3+ has a long
electronic relaxation time based on its totally symmetric
S state making it well suited for use as an MR contrast
agent. It accelerates the relaxation of the water molecules
present in the tissue, giving rise to an enhanced signal
on T1-weighted images and, together with appropriate
sequence parameters, an improved image contrast.
However, gadolinium, like most metals, interferes with
the complex biochemical processes of living organisms.
In particular, it can act as a competitive inhibitor of
calcium ions due to its large ionic radius (0.97 Å vs.
1.06 Å for Ca2+) and its high ionic charge. As a result
various physiological processes involving Ca2+ can be
influenced by the presence of Gd3+ such as Ca2+-activated
ATPase in the sarcoplasmatic reticulum of skeletal muscle
fibres, the reticuloendothelial system and some other
enzymes such as dehydrogenases and glutathione S trans-
ferases. It is also known that Gd3+ has an inhibitory effect
on Kupffer cells [4].
The toxic effects of Gd3+ can be suppressed by encasing
it in an organic chelator. A variety of such chelators have
been FDA/EMEA approved for use in patients and others
are still being investigated [12-14]. The contrast agents in
clinical use are based on the linear ionic chelator
diethylenetriamine pentaacetic acid (often dubbed as
DTPA or "pentetic acid"), the linear non-ionic chelator
benzyloxyproprionictetra- acetate (“BOPTA”) or on the
cyclic ionic chelator tetraazacyclododecane tetraacetic acid
(DOTA). Other cyclic non-ionic chelators are tetraazacycl
ododecane (DO3A). Stability of these agents is character-
ized in two ways: Thermodynamic stability describes the
tendency of the chelate to dissociate into its components
given an unlimited amount of time. It is expressed numer-
ically as the logarithm of the stability constant. Kinetic
stability describes the timescale of the dissociation
expressed either as a rate constant or a half-life. Both
characteristics depend on the surrounding milieu:
Decreasing pH and increasing temperature favour
dissociation [15]. As a rule, the macrocyclic chelates are
several orders of magnitude more stable with regard to
dissociation and transmetalation than their linear counter-
parts [16-18]. Furthermore, the presence of ions such as
Ca2+, Cu2+ or Zn2+ which can replace Gd3+ from the
chelate in a transmetalation reaction promote the un-
wanted release of Gd3+ exposing tissues to its toxic effects
[19]. Indeed, early in vivo studies using radioisotope
labelled Gd chelates indicate a relationship between kinetic
stability and tissue-uptake of gadolinium [20].
Besides the characterization in terms of macrocyclic
and linear chelate structures, the nine currently available
GBCAs (Table 1, Figure 1) can also be categorized by
ionicity. Non-ionic Gd3+ chelates cause less osmotic
stress because they do not require counterions such as
Na+ in their formulations. They are closer to ionicneutrality with lower viscosity, and are less hydrophilic
than ionic Gd3+ chelates [21]. As with iodinated contrast,
non-ionic Gd3+ chelates appear to have a lower rate of
allergic reactions [22]. Unfortunately non-ionic linear
chelates are also less stable than their negatively charged
analogs. With the exception of three linear ionic GBCAs
that have lipophilic groups in their chelate structures
(Gadobenate, Gadoxetate, Gadofosvescet), GBCAs are
eliminated exclusively via the renal pathway. The
estimated half-life of renal elimination of GBCAs for
patients with normal renal function is about 90 min.
However, with decreasing renal function the effective
half-life increases to up to 18 – 34 hours [16,23]. Within
this timescale gadolinium release for the linear chelates
may be significant [20].
Two of the three mentioned linear, ionic GBCAs
(Gadobenate, Gadoxetate) have an aromatic component
within the chelate structure that allows hepatocellular
uptake and partial excretion via the biliary pathway.
The third mentioned GBCA (Gadofosveset) has a
biphenylcyclohexyl group that reversibly binds to
albumin, extending the plasma half-life to about 18.5
hours for patients with a normal renal function [16,19].
Pathogenesis of nephrogenic systemic fibrosis
NSF occurs in patients with acute or chronic renal failure
[32,33]. The vast majority of NSF cases (approximately
95 %) have occurred in renal failure patients who received
GBCA enhanced CMR imaging techniques prior to
symptom onset [34]. Thus, it is likely that GBCAs play a
role in triggering NSF. All GBCA stimulate the proliferation
of fibroblasts, the linear GBCAs show a more potent
stimulation than macrocyclic GBCAs [35-38] which raises
the possibility that GBCA dissociation from the chelator is
not necessary for NSF to occur. One hypothesis is that
macrophages phagocytose the Gd3+ complexes that then,
being located in intracellular lysosomes, stimulate the
production of cytokines, and growth factors [39,40]. Local
inflammation may be due to local Gd3+ deposition, that is
triggered by local CD68+ or XIIIa+ dendritic cells, and a
systemic inflammatory response that is associated with
CD34+ fibrocytes that originate from the bone marrow
[41]. The heterogeneous phenotypes of cells found in NSF
lesion imply that both local and systemic inflammatory
mechanisms might coexist [42]. TGF-beta1 levels are ele-
vated in patients with NSF, and some studies have shown
increased decortin levels, alpha-smooth muscle actin and
hyaluron synthesis [38,43-45]. A modulation of collagen
syntheses with an increase of Collagen I and III production
as well as an increase in fibronectin expression has been
documented [38,46], as well as increased VEGF levels,
Ostepontin, and TIMP-1 expression [47]. At least for one of
the GBCAs (Gadodiamide), an effect on the expression of
chemokine genes has been tracked down as the presence of
Table 1 Stability of Gadolinium- based magnetic resonance imaging contrast agents in human serum at 37°C, K(therm)
Class Net Charge Trade Name Short Names Log K(therm) Log K(cond7.4) Kinetic Stabiltiy
Linear Non-ionic Omniscan Gadodiamide 16.9 14.9 Low
Non-ionic Optimark Gadoversetamide 16.8 15.0 Low
Ionic Magnevist Gadopentetate 22.5 18.4 Medium
Ionic Multihance Gadobenate 22.6 18.4 Medium
Ionic Primovist Gadoxetate 23.5 18.7 Medium
Ionic Vasovist Gadofosvescet 22.1 18.9 Medium
Macrocyclic Non-ionic Gadovist Gadobutrol 21.8 15.5 High
Non-ionic Prohance Gadoteridol 23.8 17.2 High
Ionic Dotarem Gadoterate 25.6 19.3 High
Stability constants measured at high basic pH. K(cond7.4) describe the complex stability constant at physiological conditions (pH 7.4). The values of K(cond7.4) are
smaller than the values of K(therm). Smaller values indicate less complex stability [24] [21]. The Values of K(therm) and K(cond7.4) are based on studies of Kumar,
Cacheris, Toth, Imura, Schmitt-Willich, Uggeri, Caravan and Moreau [12,25-31]. Kinetic stability describes the activation energy required to break the chelate-
Gadolinium bond.
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that exposure to GBCAs and the included Gd3+ is a potent
stimulator of normal macrophages [48]. Most recent studies
suggest that possibly other cells might be involved in the
development of NSF as well, such as tissue monocytes and
macrophages in the peripheral blood [49].
Additionally, it has been discussed that pro-inflammatory
events, like vascular thrombosis, myocardial infarction,
trauma, sepsis or recent surgery might contribute to thenon ionic 
linear 
macro-
cyclic
* *
Figure 1 Molecular structures of all currently available Gadolinium- b
are presently considered the agents with highest safety due to their macrodevelopment of NSF [33]. Sepsis might even trigger the
onset of NSF without exposure to GBCAs [50]. A resent
work showed that the presence of GBCA increases DNA
damage in lymphocytes [51]. The presence of high iron and
erythropoetin levels are suspected to contribute to the
development of NSF as well [44,52-54]. The Gd3+
complexes seem to have an effect on calcium phosphate as
a study showed that the calcium phosphate precipitation is
increased thus activating macrophages [55].Ionic
*
ased contrast agents. The three agents in the lower section (asterisk)
cyclic structure.
Table 2 Overview of the examined treatment options
Established therapies Physical Therapy
Pain control
(opoids, NSARs, steroids, antidepressants)
Renal Transplantation
Based on case reports Extracorporal photopheresis
Plasmapheresis
UV- A1 therapy
High dose iv. Immunoglobulines
Imatinib Mesylate
Rabamycine
Pentoxifylline
Anecdotal Topical dovonex
Cytoxan
Thalidomide
Immunosuppression via Steroids
The treatment is limited to symptomatic relief.
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Patients with NSF present with skin lesions typically
beginning on the distal extremities starting with
indurated plaques and papules especially on edematous
lower extremities, later on the upper extremities, trunk
and eye section develop over days to several weeks and
later show a woody texture. The plaques are described as
brawny, and the skin may develop hyperpigmentation
[56] [57]. NSF lesions usually occur symmetrically.
Patients may report sharp pain as well as pruritus,
causalgias and paresthesias in afflicted areas. Stiffness
and joint contractures can lead to decreased mobility.
The progression is rapid in an estimated 5 % of cases [8]
leading to immobility within weeks and in a few
instances death has been attributed to NSF. Besides skin
developing lesions, internal organs can be afflicted
including lung, heart, liver, bones and kidneys [33,34].
NSF diagnosis is usually postulated upon the medical
history/physical exam and confirmed with a deep punch
skin biopsy [2,56,58,59]. Eosin and hematoxylin staining
are used for demonstrating the typical features. The skin
biopsy shows a dermal fibrosis with a high density of CD
34 positive and procollagen I positive fibrocytes (circulating
fibrocytes) and collagen bundles with prominent clefts
between the bundles. Besides these collagen bundles elastic
fibres can be detected as well. Additionally, but not required
for diagnosis of NSF, factor XIIIa positive dendritic cells
may be detected [56]. However the histopathological and
clinical features can overlap with other entities. Among
these are Lipodermatosclerosis, Scleroderma and
Morphea, Scleromyxedema, Porphyria cutanea tarda,
Spanish toxic Oil syndrome, eosinophilic fasciitis and
Eosinophilia- myalgia syndrome and chronic graft
versus host disease [2,58,60]. It is necessary to combine
both the clinical features and the histopathologic
findings in order to avoid misdiagnosis.
Exposure to gadolinium might arouse suspicion
towards the diagnosis of NSF however it has to be
stressed that exposure to GBCAs does not factor into
the diagnosis. The lack of GBCA exposures does not
exclude NSF as diagnosis, as in about 5 % of NSF
patients no GBCA exposure prior to symptom onset
could be found.
Besides the development of NSF other more acute
reactions to GBCA exposure have been described.
Symptoms that imply the development of septicaemia
have been described within 12-36 h after administration
of GBCA [61]. Allergic reactions albeit rare are another
GBCA risk [22] [62]. The possibility of deterioration in
renal function after GBCA exposure in renal failure
patients is controversial but in the usually administered
dosages GBCAs are less nephrotoxic than iodinated
contrast agents even with the high doses used for MR
viability imaging and MR Angiography [63,64].Incidence and prevalence
The incidence of NSF prior to 2008 varied widely among
different institutions ranging from 0.26 % in patients on
dialysis without any contributing factors to up to 8.8 %
in patients with a eGFR smaller than 15 ml/min/1.73 m³
without hemodialysis [50,65]. A study published in 2007
in another center calculated an absolute risk for developing
NSF in patients on chronic dialysis of 2.4 % per GBCA
enhanced study and an absolute risk of 3.4 % per
patient [66]. The combination of renal insufficiency and
proinflammatory processes (e.g. operations, thrombembolic
events, endothelial/vascular injury) adds up to an NSF
incidence of 4.6 % [33]. The incidence is further increased
when renal failure patients on dialysis develop sepsis, and
has been estimated at 6.3 % [50]. It is also noteworthy that
the overwhelming majority of cases was either on dialysis or
had an eGFR < 15 ml/min/1,73 m³. Only a handful of cases
estimated in patients with an estimated GFR > 30 ml/min/
1,73 m³and most of these were patients in acute renal
failure where GFR estimation is unreliable. The incidence of
reported NSF cases in patients with a normal renal function
is zero.
The vast majority of NSF cases have been reported in
patients who underwent GBCA enhanced imaging
however, about 5 % of NSF cases showed no traceable
exposure to GBCAs prior to NSF onset [34]. The
exposure to GBCAs seems to be a cofactor to developing
NSF, with the incidence depending besides the already
mentioned patients collective also on the type and dose
of GBCA. In patients who received a GBCA dose
according to the labeling (e.g. 0.1 mmol/kg) overall
incidence is near zero, regardless of their renal function.
Based on a report of Prince (2008, [65]) the use of higher
GBCA doses such as double or triple dose GBCA
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incidence from zero to 0,17 % for some of the available
contrast agents. These were Gadodiamide and Gadobenate,
while this effect was not detected with Gadopentetate
dimeglumine and Gadoteridol. The incidence rises when
GBCAs in high doses are used in patients with renal failure.
One of the reports describes the incidence in this setting at
8.0 % [65,67-69].
The majority of reported cases are associated with
non-ionic linear contrast agents (Gadodiamide or
Gadoversetamide). Another agent associated with NSF
is Gadopentate dimeglumine, but there are markedly
fewer cases with Gadopentate dimeglumine than with
Gadodiamide in spite of Gadopentetate dimeglumine
having greater market share. Based on data presented at
the FDA Joint Meeting of the Cardiovascular and Renal
Drugs and Drug Safety Advisory Committee (Dec. 2009,
observed time frame 2005–2009), 382 cases of NSF are
related to the administration of Gadodiamide (estimated
doses 13 million worldwide), 195 cases related to the
administration of Gadopentetate dimeglumine (estimated
doses 23 million doses worldwide) and 35 cases are
attributed to Gadoversetamide (estimated 4.7 million doses
worldwide). To date, no cases have been associated with the
administration of Gadoxetate or Gadofosveset [70].Table 3 The FDA guidelines from 2006, 2007 and 2010 (www
FDA 2006 FDA 2007
Boxed Warning for GBCAs
Patients at risk: Patients at risk:
Moderate to end stage kidney disease
(GFR < 60 ml/min/1.73 m²)
Acute or chronic severe renal ins
(GFR < 30 ml/min/1.73 m²)Acute
insufficiency due to hepatorenal
syndrome or in the perioperative
of a liver transplant
Screen all patients for renal dysf
(history and/or lab tests)
Measures: Measures:
Carefully weigh pros and cons of GBCA
enhanced imaging
avoid GBCA unless absolutely ne
Use alternative imaging if possible do not exceed recommended d
take the elimination half life into
and allow enough time for GBCA
before rescanning the patient
Consider prompt dialysis in all patients
with impaired renal function
Consider prompt dialysis in patie
already on dialysis treatmentThe American NSF registry has documented over 355
proven cases of NSF so far, however, other groups have
reported deviant numbers, e.g. Zou et al. report of 408
cases that were biopsy confirmed [71]. Most likely, not
all cases have been reported to the NSF registry, but
directly to the FDA or not at all.
NSF is rarely seen in pediatric patients [72-74]. The
youngest known case of NSF is a 6 year old patient even
though many newborn babies with immature kidneys in the
past received high doses of GBCA for multiple MR scans to
assess congenital heart disease. This suggests that infants
and newborns may be a protected population [63].
Treatment of nephrogenic systemic fibrosis
Many NSF patients have improved or even been cured
with restoration of normal renal function. This has
occurred when acute renal failure resolves and with renal
transplantation. Otherwise, there is no proven effective
therapy for the treatment of NSF and to date the
treatment options are limited to symptomatic relief.
Physical therapy supposedly improves the range of
motion [75]. Pain medication usually is needed and includes
the use of opioids, NSAR´s, steroids and antidepressants. A
single case reports that acetazolamide showed a good pain
relieving effect in a meningeal affection of NSF. In some.fda.org)
FDA 2010
Change in labeling for GBCAs
Patients at risk:
ufficiency
renal
phase
Highest risk for patients with GFR < 30 ml/min/1.73 m²
Repeated or high dosage GBCA enhanced procedures
NO RISK: patients with normal kidney function
unction Screen all patients for renal dysfunction
(history for assessment of acute kidney failure,
lab tests for patients at risk for chronic renal failure)
Risk factors are Diabetes, Hypertension, heart disease,
smoking, obesity, high cholesterol, family history of
kidney disease, age 65 or older, urinary tract
infections/obstructions, systemic infections
or autoimmune diseases [91]
Measures:
cessary Gadodiamide, Gadoversetamid, Gadopentet Acid
are contraindicated for highest risk patients
ose
account
elimination
Avoid GBCAs in patients with impaired
(known/suspected) drug elimination unless
absolutely necessary
nts that are Consider prompt dialysis in patients that are
already on dialysis treatment
Monitor patients after GBCA administration,
good documentation, no repeat GBCA imaging
procedures until GBCA is eliminated from the body
Table 4 The EMA guidelines (www.ema.europa.eu)
Patients with
severely
impaired renal
function
high risk GBCAs are contraindicated
medium and low risk GBCAs: use lowest
possible dose, pause at least 7d between
two GBCA enhanced procedures
Patients with
moderately
impaired renal
function
High risk GBCAs: use single injection of
minimum dose, pause of 7d between
two GBCA enhanced procedures
Medium and low risk GBCAs: use minimum dose,
pause of 7d between two GBCA enhanced procedures
Toddlers < 1yo High, medium and low risk GBCAs: use single
injection of minimum dose, pause of 7d between
two GBCA enhanced procedures
Infants < 4wks high risk GBCAs are contraindicated
medium and low risk GBCAs: use lowest possible
dose, pause at least 7d between two GBCA
enhanced procedures
Breast feeding High risk GBCAs: pause for 24 h
Medium and low risk GBCAs: consider
pause for 24 h
Perioperative
phase of
liver transplants
high risk GBCAs are contraindicated
medium and low risk GBCAs: use lowest possible
dose, pause at least 7d between two GBCA
enhanced procedures
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the nociceptive aspects of pain. However, its application has
to be performed under continuous cardiac monitoring.
The treatment options for NSF are based on case studies
with limited numbers of patients. In the early days of NSF,
the benefits of intense hemodialysis were discussed. In
patients with end stage kidney disease approximately 98 %
of the Gadolinium that freely circulate in the blood isTable 5 Recommendations for specific patient groups by the
Chronic Kidney Disease Stage 1 or 2 No special me
(eGFR 60 to 119 ml/min/1.73 m2)
Chronic Kidney Disease Stage 3a Lowest possib
(eGFR 45- 59 ml/min/1.73 m2)
Chronic Kidney Disease Stage 3b GBCA use sho
Apply same sa
(eGFR 30- 44 ml/min/1.73 m2)
Chronic Kidney Disease Stage 4 or 5
not on chronic dialysis
If feasible, avo
owest possible
(eGFR <30 ml/min/1.73 m2)
End-stage renal disease with chronic dialysis Consider chan
Schedule the
hemodialysis(eGFR 45- 59 ml/min/1.73 m
2)
Acute kidney injury If possible avo
avoid high risk
Pregnancy If possible, avo
Pediatrics Use similar saf
30 ml/min/1.7removed with 3 hemodialysis cycles. Not more than 30 % of
the Gadolinium chelates are removed with conventional
dialysis techniques. Use of ultrapure dialysate and a high
bicarbonate concentration combined with high flow for a
duration of 5–6 h is said to achieve the best clearance rate
[76]. There are some cases where a renal transplant and the
resulting improved renal function lead to a decrease in the
NSF symptoms. Among other discussed therapy options
that were published are the extracorporal photopheresis,
plasmapheris, UV-A1 Therapy, high dose intravenous
Immunoglobulins, Imatinib Mesylate, Rabamycine and
Pentoxifylline. The NSF registry additionally mentions some
therapeutic regimens that were anecdotally reported,
namely topical Dovonex, Cytoxan and Thalidomide.
The use of oral steroids was discussed as well however
the reports on the effectiveness were inconsistent
(Table 2) [76-89].
Considering the small numbers of case reports and the
fact that NSF can possibly be avoided by preventive
measures, the focus of further attention should be
primarily on prevention.
Present guidelines in Europe and the USA - European
Medicines Agency (2010), European Society of Urogenital
Radiology (2008), FDA (2010) and American College of
Radiology (2010)
The FDA was the first agency to release a public health
advisory back in 2006 when the association of GBCA
and NSF was not as convincing. However the linkage of
high dose GBCA with NSF was suspected, accordingly
the advisory stated that only if deemed necessary
patients with advanced kidney failure (dialysis or eGFR
< 15 ml/min/1.73 m²) should receive imaging studiesAmerican College of Radiology, 2010
asures
le dose of GBCA for diagnostic studies. If possible, avoid high risk GBCAs
uld be safe if dosage is restricted to 0.1 mmol/kg or less.
fety measures as in the following group
id all contrast media. If usage is not avoidable, use l
dose, avoid high risk GBCAs, avoid readministration of GBCAs for a week
ge of imaging modality. Avoid high risk GBCAs, use lowest possible dose.
imaging study as close as possible before the next routine
session.
id any GBCA administration, regardless of eGFR. If GBCA use is necessary,
GBCAs, use lowest possible dose.
id use of GBCA, unless such an imaging study is absolutely necessary.
ety measures as in adults. Neonates can have an eGFR of less than
3 m³ but is not considered an absolute contraindication.
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collective at risk to patients with an eGFR of less than
30 ml/min/1.72 m² and also linked the induction of
NSF to the hepato-renal syndrome and liver transplants.
A screening of the renal function was proposed. GBCA
dose should not exceed the FDA approved levels. In
2010 the latest FDA recommendations explicitly
contraindicated Gadodiamide, Gadoversetamide and
Gadopentetate dimeglumine use in patients with acute
kidney disease or chronic severe kidney diseaseFigure 2 Work sheet “How to do it in adults”Work sheet “How to do
Diabetes, Hypertension, heart disease, smoking, obesity, high cholesterol, ra
tract infections/obstructions, systemic infections or autoimmune diseases [9
weight for perfusion studies, 0.1-0.2 mmol/kg body weight for late gadolin
angiography studies [100,101].(eGFR<30). In general all GBCA should be avoided in
patients with suspected or known impaired drug
elimination unless the diagnostic GBCA based study is
necessary. It is again stressed that the recommended
dosage must not be exceeded and repeat dosing should
be delayed until sufficient time has passed for the first
dose to be completely eliminated. This might be less
than one day for patients with normal renal function
but up to a week for patients for severe chronic renal
disease. The screening of the renal function and goodit in adults”. Among the risk factors for chronic kidney disease are
cial factors, family history of kidney disease, ager 65 or older, urinary
1]. Standard doses for relevant procedures are 0.05-0.1 mmol/kg body
ium enhanced studies and 0.1-0.2 mmol/kg body weight for
Table 6 Current label doses for GBCAs [102]
Gadoteridol 0.1 mmol/kg or 0.2 ml/kg
Gadoversetamide 0.1 mmol/kg or 0.2 ml/kg
Gadodiamide CNS: 0.1 mmol/kg or 0.2 ml/kg
Body: 0.05 mmol/kg or 0.1 ml/kg
Intrathoracic/intraabdominal/pelvic: 0.1 mmol/kg
or 0.2 ml/kg
Gadobenate
dimeglumine
0.1 mmol/kg or 0.2 ml/kg
Gadopentetate
dimeglumine
0.1 mmol/kg or 0.2 ml/kg
Gadofosveset 0.12 mmol/kg or 0.03 ml/kg
Gadoxetate disodium 0.025 mmol/kg or 0.1 ml/kg
Gadoterate meglumine0.1 mmol/kg or 0.2 ml/kg
Gadobutrol 0.1 mmol/kg or 0.1 ml/kg
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should be also noted, that only little data on the safety
of GBCAs for pediatric patients and almost no data for
children younger than 2 years old is available.
The European Medicines Agency (EMA) has defined
three risk classes of Gadolinium- based contrast agents.
For each of them, the EMA has defined measures to
reduce the risk of NSF.
1. High risk
Gadodiamide; Gadoversetamide, Gadopentetate
Dimeglumine
2. Intermediate risk
GadobenateDimeglumine; Gadoxetate Disodium;
Gadofosveset
3. Low risk
Gadobutrol, Gadoteridol; Gadoterate Meglumine
The EMEA’s recommendations on the use of GBCAs
are based on this classification (see Table 4). However
the concern about newborns is controversial because
there are no known cases of NSF in any patient less than
6 years old in spite of a extensive use of high doses of
gadolinium based contrast agents for evaluating congenital
heart disease in this population [63]. The guidelines also
point to the necessity of good documentation of contrast
agent type and dose [92] which has not been reliable in the
past (Table 4) [93].
The European Society of Urogenital Radiology agrees
with the EME on three risk classes for Gadolinium based
contrast agents. Additionally, the ESUR defines three risk
classes for patients. Patients with chronic kidney disease
(CKD) stage 4 and 5 (eGFR < 30 ml/min), patients on
dialysis and patients with impaired renal function and
pending or received liver transplant are considered high
risk patients. Patients with CKD stage 3 and small
children younger than 1 year old have a lower risk and
with regards to renal function healthy patients are at no
risk for developing NSF. The EUSR guidelines also
mention the treatment of pregnant women. Due to lack
of experience, these patients are to be treated according
to the protocol for infants [94].
Further preventative measures should be strived for. It is
theorized that low iron serum levels, and an optimized
Calcium, phosphate and acid base balance before injection
of GBCAs may protect against the development of NSF
[85]. Recent research has focused on the goal to limit
GBCA doses as far as possible in order to still ensure good
image quality. Some authors have reported sufficient image
quality in 3 T scanners e.g. for abdominal imaging with
0,025 mmol/kg GBCA at 3 T [95], 0,05 mmol/kg for soft
tissue characterization [96] and with 0,05 mmol/kg for vas-
cular malformations [97]. Modifications in CE-MRA proto-
cols offer further reduction of contrast agent doses [98].Guidelines of the American College for Radiology (2010)
The American College of Radiology (ACR) recommen-
dations of 2010 agree with the other guidelines on the
associations of GBCA exposure, dosage relations and
kidney function. The need for adequately assessing the
renal function has been highlighted. In the opinion of
the ACR patients at risk, e.g. patients with a past
medical history of a renal disease, aged above 60 years
old, who have hypertension or diabetes mellitus,
should be tested for their renal function 6 weeks prior
the planned CMR study. Additionally, a verbal assess-
ment might be helpful. The recommendations for the
specific patient groups, divided by their renal function
is listed in Table 5 [99].
The recommendations of the above mentioned
guidelines can be incorporated into an easy to use
short work sheet for non- pregnant adults for everyday
use (Figure 2, Table 6: list of current label doses).Conclusions
NSF is one of the major risks associated with GBCA
enhanced CMR procedures. Many of its features and
pathogenetic characteristics have been already revealed,
however important aspects still have to be focused on, for
example the treatment of NSF. For the time being, the
treatment is limited to symptomatic relieve and prevention.
Several up to date guidelines are available, explaining the
aspects of a safe GBCA enhanced CMR procedure. The
benefits of GBCA enhanced CMR techniques are many in
numbers, and should not be withheld rashly. Even with the
lack of new NSF cases, the general awareness for NSF has
to be strengthened in order to prevent the reoccurrence of
this GBCA side effect.
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